C H J Lamers

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi request reprint Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer
    Cor H J Lamers
    Department of Medical Oncology, Subdivision of Clinical and Tumor Immunology, Erasmus Medical Center Daniel, Rotterdam, The Netherlands
    Cancer Gene Ther 9:613-23. 2002
  2. doi request reprint Genetically modified T lymphocytes: more than just direct effectors
    Cor H J Lamers
    Laboratory of Experimental Tumor immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, 3008 AE Rotterdam, The Netherlands
    Immunotherapy 5:691-4. 2013
  3. doi request reprint Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity
    Cor Hj Lamers
    Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Mol Ther 21:904-12. 2013
  4. doi request reprint Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells
    Cor H J Lamers
    Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cytotherapy 15:620-6. 2013
  5. doi request reprint Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
    Cor H J Lamers
    Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Blood 117:72-82. 2011
  6. doi request reprint Gibbon ape leukemia virus poorly replicates in primary human T lymphocytes: implications for safety testing of primary human T lymphocytes transduced with GALV-pseudotyped vectors
    Cor H J Lamers
    Unit of Clinical and Tumor Immunology, Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, AE Rotterdam, The Netherlands
    J Immunother 32:272-9. 2009
  7. doi request reprint Retronectin-assisted retroviral transduction of primary human T lymphocytes under good manufacturing practice conditions: tissue culture bag critically determines cell yield
    C H J Lamers
    Laboratory of Clinical and Tumor Immunology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cytotherapy 10:406-16. 2008
  8. doi request reprint Retroviral vectors for clinical immunogene therapy are stable for up to 9 years
    C H J Lamers
    Department of Medical Oncology, Laboratory of Clinical and Tumor Immunology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Gene Ther 15:268-74. 2008
  9. ncbi request reprint Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo
    Cor H J Lamers
    Laboratory for Clinical and Tumor Immunology, Department of Medical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE, Rotterdam, The Netherlands
    Cancer Immunol Immunother 56:1875-83. 2007
  10. ncbi request reprint Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-s
    C H J Lamers
    Unit Clinical and Tumor Immunology, Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cytotherapy 8:542-53. 2006

Collaborators

Detail Information

Publications19

  1. ncbi request reprint Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer
    Cor H J Lamers
    Department of Medical Oncology, Subdivision of Clinical and Tumor Immunology, Erasmus Medical Center Daniel, Rotterdam, The Netherlands
    Cancer Gene Ther 9:613-23. 2002
    ..This clinical protocol routinely yields 30-65% scFvG250 ch-Rec(POS) T lymphocytes in both healthy donors and RCC patients...
  2. doi request reprint Genetically modified T lymphocytes: more than just direct effectors
    Cor H J Lamers
    Laboratory of Experimental Tumor immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, 3008 AE Rotterdam, The Netherlands
    Immunotherapy 5:691-4. 2013
    ..The present study further explores a potential beneficial application of the observed immunogenicity of genetically modified T cells. ..
  3. doi request reprint Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity
    Cor Hj Lamers
    Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Mol Ther 21:904-12. 2013
    ..We provide in-patient proof that the observed "on-target" toxicity is antigen-directed and can be prevented by blocking antigenic sites in off-tumor organs and allowing higher T cell doses...
  4. doi request reprint Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells
    Cor H J Lamers
    Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cytotherapy 15:620-6. 2013
    ....
  5. doi request reprint Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
    Cor H J Lamers
    Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Blood 117:72-82. 2011
    ....
  6. doi request reprint Gibbon ape leukemia virus poorly replicates in primary human T lymphocytes: implications for safety testing of primary human T lymphocytes transduced with GALV-pseudotyped vectors
    Cor H J Lamers
    Unit of Clinical and Tumor Immunology, Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, AE Rotterdam, The Netherlands
    J Immunother 32:272-9. 2009
    ....
  7. doi request reprint Retronectin-assisted retroviral transduction of primary human T lymphocytes under good manufacturing practice conditions: tissue culture bag critically determines cell yield
    C H J Lamers
    Laboratory of Clinical and Tumor Immunology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cytotherapy 10:406-16. 2008
    ..Critical to our successful clinical-scale transductions of patient T cells was the use of Retronectin in combination with Lifecell X-foldtrade mark cell culture bags...
  8. doi request reprint Retroviral vectors for clinical immunogene therapy are stable for up to 9 years
    C H J Lamers
    Department of Medical Oncology, Laboratory of Clinical and Tumor Immunology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Gene Ther 15:268-74. 2008
    ..These data provide evidence that in terms of 'life expectancy' the production and storage of clinical batches of RTVsup for gene therapy warrants the corresponding professional and financial risks...
  9. ncbi request reprint Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo
    Cor H J Lamers
    Laboratory for Clinical and Tumor Immunology, Department of Medical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE, Rotterdam, The Netherlands
    Cancer Immunol Immunother 56:1875-83. 2007
    ..Here, we investigate whether or not the in vivo activity of the infused scFv(G250)(+) T cells is reflected by changes of selected immune parameters measured in peripheral blood...
  10. ncbi request reprint Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-s
    C H J Lamers
    Unit Clinical and Tumor Immunology, Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cytotherapy 8:542-53. 2006
    ..We describe the validation of our clinical protocol for gene transduction and expansion of human T lymphocytes...
  11. ncbi request reprint Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression
    C H J Lamers
    Laboratory of Clinical and Tumor Immunology, Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, 3008 AE Rotterdam, The Netherlands
    Hum Gene Ther 16:1452-62. 2005
    ..These results suggest loss of scFv(G250) membrane expression on adoptive transfer, which would have important implications for the antitumor efficacy of this form of immunogene therapy...
  12. ncbi request reprint Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer
    C H J Lamers
    Unit of Clinical and Tumor Immunology, Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer Gene Ther 13:503-9. 2006
    ..The improved functional transduction efficiency together with a limited increase in the number of integrations per recipient cell, made us select Phoenix clone 58 for our clinical immunogene therapy study...
  13. ncbi request reprint Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes
    C H J Lamers
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Biol Regul Homeost Agents 18:134-40. 2004
    ..Currently, we evaluate this concept in a clinical protocol to treat patients with metastatic renal cell cancer (RCC) using autologous RCC-specific gene-modified T lymphocytes...
  14. ncbi request reprint T-lymphocyte reconstitution following rigorously T-cell-depleted versus unmodified autologous stem cell transplants
    P A W te Boekhorst
    Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands
    Bone Marrow Transplant 37:763-72. 2006
    ..This susceptibility to apoptosis would interfere with a swift and sustained CD4(+) T-cell regeneration post SCT...
  15. doi request reprint Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis
    T Mondria
    Department of Neurology, Erasmus University Medical School, Erasmus MC, 3000 CA Rotterdam, The Netherlands
    J Neurol Neurosurg Psychiatry 79:1013-5. 2008
    ..Given the presumed key role for autoreactive lymphocytes in multiple sclerosis (MS), treatment strategies have been developed to ablate lymphocyte activity. Intrathecal lymphocyte activation can be measured by CSF-soluble(s)CD27...
  16. ncbi request reprint Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses
    Johanna E A Portielje
    Department of Medical Oncology, Erasmus MC Daniel den Hoed, 3075 EA Rotterdam, The Netherlands
    Clin Cancer Res 9:76-83. 2003
    ..Induction of IFN-gamma, considered a key mediator of antitumor effects of IL-12, is known to decline on repeated administrations. We studied whether other immunological effects of rHuIL-12 are tapered in the course of treatment...
  17. doi request reprint mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells
    Michiel H Strijbos
    Laboratory of Translational Tumorimmunolgy, Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Thromb Haemost 104:318-26. 2010
    ..We conclude that mRNA levels of CD31, CD144, CD146 and vWf in whole blood as detected by real time RT-PCR cannot be used as biomarkers for end-stage endothelial cells such as CEC...
  18. ncbi request reprint Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors
    Valérie Vantomme
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    J Immunother 27:124-35. 2004
    ..It is concluded that vaccination of advanced cancer patients with MAGE-3 self-antigen in AS02B adjuvant is able to elicit MAGE-3-specific antibody and a T-cell response...
  19. ncbi request reprint Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience
    Cor H J Lamers
    J Clin Oncol 24:e20-2. 2006